f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Continued Follow-Up of G170301 Clinical Study


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Ongoing
Application Number /
Requirement Number		 P200036 / PAS001
Date Original Protocol Accepted 03/01/2022
Date Current Protocol Accepted 07/15/2022
Study Name Continued Follow-Up of G170301 Clinical Study
Device Name eCoin Peripheral Neurostimulator
General Study Protocol Parameters
Study Design Active Surveillance
Data Source Other Data Source
Comparison Group Device Subjects Serve as Own Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives Continued follow-up of premarket cohort to obtain longer term safety and effectiveness data on the eCoin out to 5 years post-implantation
Study Population Subjects diagnosed with Urgency Urinary Incontinence (UUI).
Sample Size Available sample size for longer term follow-up of the original cohort.
The original IDE study was designed to enroll and implant between 120 and 135 patients; it enrolled 137 patients with 4 patients exiting prior to implantation (due to ineligibility). Thus, 133 patients were implanted.
Key Study Endpoints To collect and report clinical outcomes for safety and effectiveness, including 3-day bladder diaries, all device- or procedure-related adverse events, including but not limited to, infections, vasculitis, cellulitis, neuro-sensory and -motor events, device migrations, erosions, unplanned explantations, and re-implantation, to FDA through 5 years post-implantation on patients enrolled in G170301.

Follow-up Visits and Length of Follow-up 5 years, post-implantation


Continued Follow-Up of G170301 Clinical Study Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 08/30/2022 08/31/2022 Overdue/Received
1 year report 03/01/2023 02/24/2023 On Time
18 month report 08/30/2023 08/24/2023 On Time
2 year report 02/29/2024 02/26/2024 On Time
3 year report 03/01/2025    


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-